BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 871 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 871 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $270.42, for a total transaction of $235,535.82. Following the completion of the transaction, the senior vice president owned 160 shares in the company, valued at $43,267.20. This represents a 84.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total transaction of $103,159.04.
• On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $311.59, for a total transaction of $103,447.88.

BeOne Medicines Price Performance

Shares of ONC stock opened at $263.61 on Thursday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a market capitalization of $28.92 billion, a P/E ratio of 58.97 and a beta of 0.49. The company’s 50-day simple moving average is $301.03 and its two-hundred day simple moving average is $315.60. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. As a group, equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds and other institutional investors have recently modified their holdings of ONC. EFG International AG bought a new position in shares of BeOne Medicines during the fourth quarter valued at approximately $25,000. Leonteq Securities AG purchased a new stake in BeOne Medicines during the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. purchased a new stake in BeOne Medicines during the second quarter valued at approximately $35,000. CWM LLC lifted its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Group One Trading LLC purchased a new stake in BeOne Medicines during the fourth quarter valued at approximately $61,000. 48.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ONC has been the subject of a number of research reports. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Royal Bank Of Canada increased their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Guggenheim increased their price objective on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley reiterated an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.